ATSN-401, Atsena Therapeutics’ investigational gene therapy for Stargardt disease, has [...]
AAVantgarde’s AAVB-039 gene therapy, targeting the root cause of Stargardt [...]
Ascidian Therapeutics has appointed Murray Abramson as chief development officer. [...]